Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification (NATURE-ETN) is a European Training Network (ETN) project funded from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions co-ordinated by Prof. Andrew Kellett at DCU. Partners involved in this ETN include: accelopment AG, CH (Partner Organisation), Ludwig-Maximilian-Universität München (DE), University of Oxford (UK), Université de Recherche Paris Sciences et Lettres (FR), Ustav Organicke Chemie a Biochemie (CZ), University of Reading (UK), Uniwersytet Warszawski (PL), ATDBio Ltd (UK), Baseclick GmbH (DE) and National Institute for Bioprocessing Research and Training Ltd (IE). This multisectoral consortium is focused on nucleic acid immunotherapy, gene editing, DNA crystallography, and epigenetic DNA sequencing technology.

This ETN will leverage recent breakthrough discoveries in epigenetic manipulation, gene editing, small molecule DNA targeting, and rapid gene/transgene detection to extend the boundaries of molecular medicine and provide new tools for treating cancer and monogenetic diseases. 15 Early Stage Researchers (ESRs) trained within NATURE-ETN will acquire the necessary knowledge and skillset to fill high-functioning industry jobs in the biotechnology and biopharmaceutical industries, but also to maintain and advance Europe’s competitiveness and innovation capacity.

Read the press release from DCU here